Ipamorelin

Ipamorelin Specification

Items Specifications Results
Appearance White powder Conforms
Purity(HPLC) ≥98% 99.65%
Single Impurity (HPLC) ≤1.0% Conforms
Acetate Content(HPLC) ≤15.0% 10.20%
Peptide Content (N%) ≥80.0% 84.50%
Water Content (Karl Fischer) ≤10.0% 3.50%
Mass Balance 95.0~105.0% Conforms

Description

Ipamorelin is a new and effective synthetic pentapeptide , with obvious features, and  specific

hormone (GH) – release properties, so that getting a lot of attention in the bodybuilding world.

Such properties interested by athletes and bodybuilders since they can make a tremendous

difference in the amount of muscle growth and burn fat quickly.

Ipamorelin doesn’t create bumps in either prolactin or cortisol like ghrp-2 and -6. ipa is a rifle

bullet, not a shotgun blast like other ghrp’s. also it’s great for those on relatively calorie

restricted diets because it doesn’t stimulate appetite.

Application

Ipamorelin is a g protein-coupled receptor that binds ghrelin and plays a role in energy homeostasis

and regulation of bodyweight. It has objective of effects on longitudinal bone growth rate, and gh release.

Packing

2mg/via, 10 vials/carton

1g/foil bag

Storage

Cool dry place( 2-8oC, away from the light)

Dosage and usage

Ipamorelin is an interesting peptide that takes 300mcg twice a day, or you can reduce it by 3 times a day.

The side effect is head sprint. We recommend taking this 30 minutes before before exercise with gear.

To investigate the effects on longitudinal bone growth rate, body weight and GH release, different doses

(0, 18, 90 and 450 μg/day) of ipamorelin were injected three times a day for 15 days. It was also pronounced

that dose-dependent effects on body weight gain. The treatment did not affect total igf-i levels, or serum

markers of bone formation and resorption. the number of tartrate-resistant acid phosphatase-positive

multinuclear cells in the metaphysis of the tibia did not change significantly. Whether ipamorelin or other

gh secretagogues have a place in the treatment of children with growth retardation, it requires demonstration

clinical studies in the future.